Windel Plus Nebuliser Solution 2.5mg+0.5mg

PRESENTATION

Windel® Plus: Each ampoule contains 2.5 ml isotonic, clear solution for inhalation of salbutamol sulphate BP equivalent to

Salbutamol 2.5 mg and Ipratropium Bromide BP equivalent to Ipratropium 0.5 mg.

DESCRIPTION

Windel Plus contains two active bronchodilating substances, Salbutamol Sulphate and Ipratropium Bromide. Salbutamol Sulphate is a

beta2-adrenergic agent which acts on airway smooth muscle resulting in relaxation. Salbutamol relaxes all smooth muscle from the

trachea to the terminal bronchioles and protects against all bronchoconstrictor challenges. Ipratropium Bromide is a quaternary

ammonium compound with anticholinergic properties. In preclinical studies, it appears to inhibit vagally mediated reflexes by

antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the

increase of intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) caused by interaction of acetylcholine with

muscarinic receptors on bronchial smooth muscle. The bronchodilation following inhalation of Ipratropium Bromide is primarily

local and site specific to the lung and not systemic in nature. Windel Plus provides the simultaneous release of Ipratropium

Bromide and Salbutamol allowing the synergistic efficacy on the muscarinic and beta2-adrenergic receptors in the airways to cause

bronchodilation which is superior to that provided by each single agent and with no potentiation of adverse events.

INDICATIONS

Windel Plus is indicated for the treatment of reversible bronchospasm associated with obstructive airway diseases in patients who

require more than a single bronchodilator.

DOSAGE & ADMINISTRATION

Windel Plus inhalation solution in ampoule may be administered from a suitable nebuliser or an intermittent positive pressure

ventilator.

Adults (including elderly): One ampoule as required for the relief of symptoms or as directed. Up to three to four ampoules daily.

Patients should be advised to consult a doctor or the nearest hospital immediately in the case of acute or rapidly worsening

dyspnoea if additional inhalations do not produce an adequate improvement.

SIDE EFFECTS

Windel Plus inhalation solution in ampoule may be administered from a suitable nebuliser or an intermittent positive pressure

ventilator.

Adults (including elderly): One ampoule as required for the relief of symptoms or as directed. Up to three to four ampoules daily.

Patients should be advised to consult a doctor or the nearest hospital immediately in the case of acute or rapidly worsening

dyspnoea if additional inhalations do not produce an adequate improvement.

PRECAUTIONS

N/A

USE IN PREGNANCY & LACTATION

Although there is little published evidence of the safety of combination of Salbutamol & Ipratropium Bromide in the early stages

of pregnancy, the individual active ingredients, Ipratropium Bromide and Salbutamol have been in widespread use for many years. No

suspect teratogenic factors have been observed in general practice or clinical studies. As a general precaution, however, Windel

Plus should only be used in pregnancy and during the lactation period if the expected benefit to the mother is greater than any

possible risk to the child.

Windel Plus should be used with caution before childbirth in view of Salbutamol's inhibitory effects on uterine contractions.

Salbutamol Sulphate and Ipratropium Bromide are probably excreted in breast milk and their effects on neonates are not known.

Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that this will happen to any extent especially

when taken by inhalation. However, because many drugs are excreted in breast milk, caution should be exercised when Windel Plus is

administered to a nursing woman.

DRUG INTERACTION

The concurrent administration of other beta-mimetics, systemically absorbed anticholinergics and xanthine derivatives may increase

the side effects.

Beta-agonist induced hypokalaemia may be increased by concomitant treatment with xanthine derivatives, glucocorticosteroids and

diuretics. This should be taken into account particularly in patients with severe airway obstruction.

Hypokalaemia may result in an increased susceptibility to arrhythmias in patients receiving digoxin. It is recommended that serum

potassium levels be monitored in such situations.

A potentially serious reduction in bronchodilator effect may occur during concurrent administration of beta-blockers.

Beta-adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or

tricyclic antidepressants, since the action of beta-adrenergic agonists may be enhanced.

Inhalation of halogenated hydrocarbon anaesthetics such as halothane, trichloroethylene and enflurane may increase the

susceptibility to the cardiovascular effects of beta-agonists.

OVER DOSE

The effects of overdosage are expected to be primarily related to Salbutamol because acute overdosage with Ipratropium Bromide is

unlikely as it is not well absorbed systemically after inhalation or oral administration.

Symptoms

Manifestations of overdosage with Salbutamol may include tachycardia, anginal pain, hypertension, hypotension , palpitations,

tremor, widening of the pulse pressure, arrhythmia and flushing.

Therapy

Administration of sedatives, tranquillisers.

In severe cases, intensive therapy.

Beta-receptor blockers, preferably beta1-selective, are suitable as specific antidotes; however, a possible increase in bronchial

obstruction must be taken into account and the dose should be adjusted carefully in patients suffering from bronchial asthma.

STORAGE

Store below 30°C (86°F).

COMMERCIAL PACK

Windel Plus®: Each box contains 10 ampoules in blister packs.